Streetbeat News

Stock Prices

PSMT

PriceSmart, Inc. (NASDAQ:PSMT) reported lower than expected earnings for Q4 2023, but sales exceeded estimates. The company's adjusted earnings were 65 cents per share, missing market estimates of 85 cents per share. Revenue was $1.118 billion, above expectations of $1.096 billion. The company's dividend yield is currently 1.28%, or $0.92 a year. To generate a monthly dividend income of $500, an investor would need to own approximately $467,432 worth of PriceSmart, or 6,522 shares. PriceSmart shares fell 0.7% to close at $71.67 on Monday.

Portfolio Pulse from Lisa Levin

October 31, 2023 | 12:23 pm

BRSH

BYND

EL

OTLY

RMCF

The article lists five oversold stocks in the consumer staples sector that could potentially rescue a portfolio. The companies mentioned are Bruush Oral Care Inc. (BRSH), Oatly Group AB (OTLY), The Estée Lauder Companies Inc. (EL), Rocky Mountain Chocolate Factory, Inc. (RMCF), and Beyond Meat, Inc. (BYND). All these stocks have an RSI value below 30, indicating they are oversold and could be undervalued.

Portfolio Pulse from Lisa Levin

October 31, 2023 | 12:22 pm

NXRT

NexPoint Residential (NYSE:NXRT) reported Q3 core FFO per share of $0.65, down from $0.84 the previous year. The company's quarterly sales were $69.80 million, missing the analyst consensus estimate of $70.15 million by 0.50 percent. However, this represents a 2.57 percent increase over sales of $68.05 million the same period last year.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 12:19 pm

ANET

Arista Networks Inc's shares are up by around 10% following the release of their Q3 FY23 results. The company reported a 28.3% Y/Y revenue growth to $1.509 billion, surpassing the consensus of $1.480 billion. Adjusted EPS was $1.83, beating the consensus of $1.58. The company's Q4 FY23 outlook expects revenues of $1.500 billion-$1.550 billion, adjusted gross margin of around 63%, and adjusted operating margin of approximately 42%.

Portfolio Pulse from Lekha Gupta

October 31, 2023 | 12:18 pm

AAPL

TSM

Apple has launched its latest Mac products featuring in-house developed M3 series processors, manufactured by TSMC. However, the supply chain has not seen a significant increase in related orders for the holiday season.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 12:16 pm

ADAP

Adaptimmune Therapeutics (NASDAQ:ADAP) has reported positive outcomes for patients with synovial sarcoma who received afami-cel in the SPEARHEAD-1 trial. The trial showed a 39% clinical response rate with a median duration of response of 12 months. The median overall survival was 17 months, compared to a historical median of less than 12 months for patients who received two or more prior lines of therapy. Adaptimmune is on track to make afami-cel its first commercial product, with the completion of the Biologics License Application (BLA) targeted for Q4 2023.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 12:14 pm

DOGEUSD

FLOKIUSD

PEPEUSD

Crypto analyst Rekt Capital predicts a potential decline for Dogecoin (DOGE), noting a complicated weekly close below the Channel Top resistance. However, if DOGE can reclaim the Channel Top as support, there may still be a chance for a breakout. Other analysts, including Ali Martinez and Crypto Tony, express optimism about DOGE's recent breakout and the rising popularity of meme coins such as Floki (FLOKI) and Pepe Coin (PEPE).

Portfolio Pulse from Mehab Qureshi

October 31, 2023 | 12:14 pm

WKSP

Worksport Ltd. (NASDAQ:WKSP) has announced a securities purchase agreement with an institutional investor for a registered direct offering and concurrent private placement. The company will sell 3.5 million shares of common stock or pre-funded warrants at $1.34 each, and issue warrants for up to 7 million shares of common stock. The gross proceeds are estimated to be around $4.7 million, which will be used for working capital and general corporate purposes. The offering is expected to close on November 2, 2023.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 12:13 pm

RHHBY

SRPT

Sarepta Therapeutics Inc (NASDAQ:SRPT) released topline results from its Phase 3 study of Elevidys, a gene therapy for Duchenne muscular dystrophy. The results showed improvements in patients but did not reach statistical significance. The news led to a 43.8% drop in SRPT shares. Roche Holdings AG (OTC: RHHBY) is collaborating with Sarepta on this project.

Portfolio Pulse from Vandana Singh

October 31, 2023 | 12:13 pm

BA

Northcoast Research analyst Chris Olin has upgraded Boeing (NYSE:BA) from Neutral to Buy and set a price target of $217.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 12:12 pm